-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the PDB drug comprehensive database sample hospital market in the second quarter of 2022 data is freshly released
.
In order to better understand the characteristics of the hospital drug market in Q2 2022, we have collated hospital medication data from Q1 2018 to Q2 2022, as shown in
Figure 1.
The annual market showed continuous growth in Q1-3, with a downward trend in Q4 until Q2 2022 was broken
.
Figure 1: Changes in the 2018Q1-2022Q2 sample hospital drug market
In the Q2 quarter of 2022, the overall sales of the sample hospital drug market was 54 billion yuan, down 4.
Although the growth of the hospital drug market in the Q2 quarter of 2022 is relatively abnormal, if you look at it from the perspective of market size, the difference between the data of Q2 and the market size of the previous quarters is not large, and the overall situation is still fluctuating within a reasonable range, and the line of sight is going back, from the Q1 quarter of 2020 sales to the bottom, to the rebound growth of Q2 in 2020, and then to the explosive growth in Q3 quarter, the abnormality of the hospital drug market in 2020 may be more obvious
.
The difference between the data of Q2 and the market size of the previous quarters is not large, and the overall is still fluctuating within a reasonable range.
Since 2020, the hospital drug market has been in transition, but it has never exceeded the peak
of Q3 of 2019.
Among the top ten drug supply enterprises in the second quarter of 2022, domestic pharmaceutical companies and multinational pharmaceutical companies are equally divided, with 5 each, all of which are well-known large pharmaceutical companies
.
Domestic pharmaceutical companies and multinational pharmaceutical companies are equally divided, with 5 each, all of which are familiar to large pharmaceutical companies
.
The top ten major treatment categories in the second quarter of 2022 have not changed much compared with the same period last year, indicating that the disease spectrum changes and patient needs are relatively stable
.
The ten major treatment categories have not changed much compared with the same period last year, indicating that the disease spectrum changes and patient needs are relatively stable
.
The change in the top ten generic drugs in the second quarter of 2022 is relatively large, because it has the smallest base and more
influencing factors than enterprises and treatment categories.
The ranking of targeted anti-cancer drugs has risen, and the ranking of non-targeted anti-cancer drugs has declined, or reflects the trend
that the hospital drug market is shifting to precision drugs.
